Table 3. Development of aEAE in SJL/J... | American Society of Hematology

Table 3.

Development of aEAE in SJL/J Mice Treated With a Single Injection of Anti–E-Selectin and/or Anti–P Selectin MoAbs

Treatment	No. of Animals	No. of Animals Developing Clinical Disease	Mean Day of Onset of Clinical Disease^3-150	Mean Severity of Clinical Disease at Day 14 p.I.
PBS	4	4	10.5 ± 0.5	3 ± 1
PS/2	6	5	14 ± 0.5^3-151	0.5
RB40 + UZ4	7	7	10.5 ± 0.5	3 ± 0.5
RB40	2	2	11 ± 0	3.5 ± 0.5

Treatment	No. of Animals	No. of Animals Developing Clinical Disease	Mean Day of Onset of Clinical Disease^3-150	Mean Severity of Clinical Disease at Day 14 p.I.
PBS	4	4	10.5 ± 0.5	3 ± 1
PS/2	6	5	14 ± 0.5^3-151	0.5
RB40 + UZ4	7	7	10.5 ± 0.5	3 ± 0.5
RB40	2	2	11 ± 0	3.5 ± 0.5

400 μg MoAb were injected IV on day 9 postimmunization (p.I.).

Only animals developing clinical disease were taken into account.

Significant difference in mean day of onset of disease (Student t-test).